The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | VRAT for monitoring ocular toxicity with belantamab mafodotin
Rakesh Popat, MBBS, MRCP, FRCPath, PhD, University College London Hospitals, London, UK, discusses the Visual Related Assessment Tool (VRAT) and its potential role in monitoring ocular toxicity associated with belantamab mafodotin. He highlights interim ProMMise-D results showing high specificity and negative predictive value for significant keratopathy, while noting the importance of healthcare professional training to improve the accuracy and reproducibility of this patient-reported assessment. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
